Posts

How the FDA is unwinding the Makary era and making way for a new commissioner (2026 update)

on

TrumpRx adds more than 600 generic meds, building on one success in US pricing

on

Trump Administration Indefinitely Delays Medicare Weight-Loss Drug Pilot Program

on

FDA Commissioner Makary Warns of US Lagging Behind China in Biotech Amid Proposed Budget and Reforms

on

RFK Jr. Reshuffles HHS Leadership Amid Midterm Focus

on

White House Launches TrumpRx.gov as Key Pillar of Most Favored Nation Drug Pricing Deals

on

CMS Selects Trulicity and Biktarvy Among 15 Drugs for Third Medicare Price Negotiation Cycle

on

SBA Defends 8(a) Program Reforms Amid Constitutional Challenges and Increased Scrutiny in 2026

on

Trump Administration Overhauls Childhood Vaccine Schedule, Reducing Recommendations and Sparking Industry Backlash

on

FDA Policy Tracker: 2025 Was a Year of Change

on

Drugmakers with White House MFN Deals Claim Exemption from Proposed Medicare Pricing Tests

on

White House unveils nine new “most-favored-nation” drug pricing deals

on

UK Agrees to Increase Drug Spending by 25% to Avoid US Pharma Tariffs

on

Lilly and Novo Nordisk Near White House Deal to Cut Obesity Drug Prices

on

Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027

on

White House Announces New Most-Favored Nation Drug Pricing Deal, Updates on FDA Vouchers and GLP-1 Negotiations

on

White House ‘Most Favored Nation’ Deadline Drives Pharma Concessions Amid Threats of Enforcement

on

Trump Administration May Exempt Some Pharma Products from Future Tariffs in Trade Policy Shift

on

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

on

Tariffs and MFN Policy Power a Broad, Confusing Pharma War

on